Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2022Antimicrobial Agents and ChemotherapyOpen Access

Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

DNDereje A. NegatuAIDS Clinical Trials GroupMZMatthew ZimmermanUniversity of Minnesota Medical CenterVDVéronique DartoisHackensack Meridian Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Negatu et al. (2022) studied this question.

synapsesocial.com/papers/6a8b008dc716e89f35dece40https://doi.org/10.1128/aac.00790-22
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action2022 · 46 citations
  2. 2Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections2021 · 43 citations
  3. 3Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future2018 · 43 citations
  4. 4Draft Genome Sequence of Mycobacterium abscessus Bamboo2017 · 37 citations
  5. 5Orally Absorbed Derivatives of the β-Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs2018 · 52 citations